CN108158988A - The preparation method of Milrinone injection - Google Patents
The preparation method of Milrinone injection Download PDFInfo
- Publication number
- CN108158988A CN108158988A CN201810164860.7A CN201810164860A CN108158988A CN 108158988 A CN108158988 A CN 108158988A CN 201810164860 A CN201810164860 A CN 201810164860A CN 108158988 A CN108158988 A CN 108158988A
- Authority
- CN
- China
- Prior art keywords
- milrinone
- injection
- solution
- preparation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
The present invention provides a kind of preparation methods of Milrinone injection, include the following steps：A, the 7/10 9/10 of water for injection dosage are measured and are heated, are passed through nitrogen, and keep being passed through nitrogen always in process for preparation, lactic acid is slowly added to and the pH value of solution is adjusted；B, to adding in milrinone after the solution high-speed stirred that is prepared in step a, until it is completely dissolved；C, the solution prepared into step b adds in sodium chloride, stirs to it and is completely dissolved；D, the solution prepared into step c adds in sodium hydroxide solution；E, the water for injection of remaining dosage is added, carries out refined filtration and ultrafiltration after being sufficiently stirred successively.The preparation method of Milrinone injection of the present invention, oxidation of the environmental factor to drug can be reduced by being passed through nitrogen, by hot injection water and add lactic acid, it can accelerate the dissolving of milrinone, carrying out refined filtration and ultrafiltration successively can effectively reduce in medicine production process and be lost, while also have the effect for improving Milrinone injection clarity.
Description
Technical field
The present invention relates to pharmaceutical preparations technology field, more particularly to a kind of preparation method of Milrinone injection.
Background technology
Milrinone is a kind of Pimobendane, is the similar drugs of Amrinone, has positive inotropic action and blood concurrently
Enlargement of pipe acts on, but its effect is 10~30 times strong compared with Amrinone.Suitable for treating nothing to digitalis, diuretics, vasodilator
Acute and chronic toys-making industry caused by a variety of causes of effect or less effective.
Milrinone is white crystalline powder, almost insoluble in water or in ethyl alcohol, slightly molten in dilute hydrochloric acid.The acid of milrinone
It is 9.67 to spend coefficient pKa constants.Since drug solubility is poor, acidic materials are often added in preparation process and help medicine
The dissolving of object, but dissolution time is still longer, and the clarity of product is susceptible to unqualified, easily becomes in storage process
Color, and store and improper can also shorten the shelf-life.
Publication number CN102579329B is disclosed adds in meglumine as cosolvent in prescription, and vitamin C is as antioxygen
Agent, to improve the stability of drug；Publication number CN105796487A is disclosed adds vitamin E and gluathione in prescription
Peptide, to improve drug quality, but the introducing of additional pharmaceutic adjuvant, while drug quality is improved, also to the peace of injection
Full property generates potential hidden danger.
In addition, in order to remove the pyrogen in Milrinone injection, the prior art tests table by the way of activated carbon adsorption
Bright activated carbon is more to milrinone absorption while pyrogen is adsorbed, and the loss using this mode drug is larger, and follow-up
It is difficult to absolutely filter out in filtering out, cause a hidden trouble to the use of patient.
Invention content
In view of this, the present invention is directed to propose a kind of preparation method of Milrinone injection, with rapidly dissolvable milrinone,
And it effectively reduces and is lost in medicine production process.
In order to achieve the above objectives, the technical proposal of the invention is realized in this way：
A kind of preparation method of Milrinone injection, the dispensing of the Milrinone injection are：Milrinone, lactic acid, chlorination
Sodium and water for injection, it is characterised in that the preparation method of the Milrinone injection includes the following steps：
A, 7/10-9/10 and the heating of the water for injection dosage are measured, nitrogen is passed through after heating, and keeps preparing
Always nitrogen is passed through in journey, the lactic acid is slowly added to and the pH value of solution is adjusted；
B, to the solution high-speed stirred prepared in step a, while the milrinone is added in, until it is completely dissolved；
C, the solution prepared into step b adds in the sodium chloride, stirs to it and is completely dissolved；
D, the solution prepared into step c adds in sodium hydroxide solution, to adjust the pH value of solution；
E, the water for injection of remaining dosage is added, carries out refined filtration and ultrafiltration after being sufficiently stirred successively.
Further, the dosage of the Milrinone injection is as follows：
Milrinone 3-6g
Sodium chloride 40-45g
Appropriate water for injection, the solution for making preparation are 5L.
Further, the heating temperature of water for injection is 60-65 DEG C in step a.
Further, the pH value of solution is adjusted to 1.6-2.0 in step a.
Further, a concentration of the 10% of the sodium hydroxide solution.
Further, the pH value of solution is adjusted to 2.9-3.4 in step d.
Further, 0.22 μm of miillpore filter is used during refined filtration.
Further, in step e, ultrafiltration will be carried out after solution refined filtration.
Further, there are step f, the filling sealing of the solution for preparing step e after step e, then in hot pressing environment
Lower sterilizing.
Further, the temperature of the hot pressing environment is 115 DEG C, pressure 97kPa, and sterilization time is 15 minutes.
Relative to the prior art, the present invention has the advantage that：
(1) preparation method of Milrinone injection of the present invention, environmental factor can be reduced to drug by being passed through nitrogen
Oxidation, by hot injection water and adds lactic acid, can accelerate the dissolving of milrinone, and carrying out refined filtration and ultrafiltration successively can effectively drop
It is lost in low medicine production process, while also there is the effect for improving Milrinone injection clarity.
(2) setting parenteral solution heating temperature is 60-65 DEG C, pH value 1.6-2.0, and the two, which be combined with each other, can make milrinone fast
Speed is dissolved into water for injection；Sodium chloride can be used for adjusting as osmotic pressure regulator the osmotic pressure of parenteral solution and human body osmotic pressure
Unanimously.
(3) lactic acid is used as the acid PH conditioning agents of parenteral solution, and regulative mode is safe and reliable.
(4) sodium hydroxide solution is used as the alkaline PH conditioning agents of parenteral solution, is combined with the lactic acid in solution and can reach tool
The pH value adjustment of body, regulative mode are simple and convenient.
(5) pyrogen in parenteral solution is removed followed by using ultrafiltration mode after refined filtration, it is efficiently convenient, reduce traditional work
The drug loss that property charcoal suction type is brought, and avoid the potential security risk of activated carbon.
(6) setting hot pressing environment temperature is 115 DEG C, pressure 97kPa, and sterilization time is 15 minutes, and triplicity can be realized
Sterilizing to parenteral solution.
Specific embodiment
It should be noted that in the absence of conflict, the feature in embodiment and embodiment in the present invention can phase
Mutually combination.
Below in conjunction with embodiment, the present invention will be described in detail.
Embodiment one
A kind of preparation method of Milrinone injection, wherein the dosage of the Milrinone injection is：
Milrinone 5g
Sodium chloride 42.5g
Water for injection is to 5L
1000 parenteral solutions can be prepared into according to more than dosage.
The preparation method of Milrinone injection includes the following steps：
A, 4L waters for injection are measured and are heated to 60-65 DEG C, nitrogen is passed through after heating, and keep always leading in process for preparation
Enter nitrogen, be slowly added to lactic acid and the pH value of solution is adjusted to 1.6-2.0；
B, to the solution high-speed stirred prepared in step a, while 5g milrinones are added in, until it is completely dissolved；
C, the solution prepared into step b adds in 42.5g sodium chloride, stirs to it and is completely dissolved；
D, the solution prepared into step c adds in a concentration of 10% sodium hydroxide solution, to adjust the pH value of solution extremely
2.9-3.4；
E, adding the water for injection of remaining dosage makes the solution of preparation be 5L, carries out refined filtration after being sufficiently stirred successively and surpasses
Filter.
Wherein：Nitrogen is passed through in step a can reduce oxidation of the environmental factor to drug, and the heating temperature of water for injection is preferred
It it is 60 DEG C, lactic acid adjusts the pH to 1.6 of solution, and more than triplicity can accelerate the solution rate of milrinone in water for injection, together
When lactic acid be used as the acid PH conditioning agents of parenteral solution, regulative mode is safe and reliable.
The rotating speed of step b high speeds stirring is not less than 200rpm, so that each material is put into solution is sufficiently mixed dissolving.
Stirring, which adds in sodium chloride, in step c can promote its dissolving, and sodium chloride can be used for adjusting as osmotic pressure regulator
The osmotic pressure of parenteral solution is consistent with human body osmotic pressure, prevents parenteral solution hypotonic and the hypertonic damage to human body.
Sodium hydroxide solution is used as the alkaline ph value conditioning agent of parenteral solution in step d, and the lactic acid added in energy and solution is anti-
Should, the pH value of parenteral solution is turned up, pH value is adjusted to 3.2 in the present embodiment, regulative mode is simple and convenient.
0.22 μm of miillpore filter is used in step e during refined filtration, particulate matter is filtered out, improves the clear and bright of parenteral solution
Degree；Pyrogen in parenteral solution is removed followed by using ultrafiltration mode after refined filtration, it is efficiently convenient, reduce traditional activated carbon adsorption
The drug loss that mode is brought, and the potential security risk of activated carbon is avoided, in addition, ultrafiltration is using molecular cut off 10,000
Sulfonated polyether sulfone film (SPES), pyrogen is filtered out to realize.
There are step f, the filling sealing of the solution for preparing step e after step e, then sterilize under hot pressing environment.
The temperature that hot pressing environment is set in the present embodiment is 115 DEG C, pressure 97kPa, and sterilization time is 15 minutes, San Zhexiang
It mutually combines to carry out sterilization treatment to parenteral solution.
The preparation method of Milrinone injection of the present invention, oxygen of the environmental factor to drug can be reduced by being passed through nitrogen
Change, by hot injection water and add lactic acid, the dissolving of milrinone can be accelerated, carrying out refined filtration and ultrafiltration successively can effectively reduce
It is lost in medicine production process, while also there is the effect for improving Milrinone injection clarity.
Embodiment two
A kind of preparation method of Milrinone injection, wherein the dosage (1000 parenteral solutions) of the Milrinone injection
For：
Milrinone 6g
Sodium chloride 40g
Water for injection is to 5L
The preparation method of Milrinone injection includes the following steps：
A, 4L waters for injection are measured and are heated to 60-65 DEG C, nitrogen is passed through after heating, and keep always leading in process for preparation
Enter nitrogen, be slowly added to lactic acid and the pH value of solution is adjusted to 1.6-2.0；
B, to the solution high-speed stirred prepared in step a, speed of agitator is not less than 200rpm, while 6g is added in into solution
Milrinone, until it is completely dissolved；
C, the solution prepared into step b adds in 40g sodium chloride, stirs to it and is completely dissolved；
D, the solution prepared into step c adds in a concentration of 10% sodium hydroxide solution, to adjust the pH value of solution extremely
2.9-3.4；
E, adding the water for injection of remaining dosage makes the solution of preparation be 5L, carries out refined filtration after being sufficiently stirred successively and surpasses
Filter.
In the present embodiment, the heating temperature of water for injection is preferably 63 DEG C in step a, and lactic acid adjusts the pH to 2.0 of solution,
PH value is adjusted to 3.4 by sodium hydroxide solution in step d.
There is step f after step e, then the filling sealing of solution prepared by step e sterilizes under hot pressing environment,
And it is 115 DEG C, pressure 97kPa to set the temperature of hot pressing environment, sterilization time is 15 minutes, to be carried out at sterilizing to parenteral solution
Reason.
Advantageous effect in the present embodiment is with consistent in embodiment one, and details are not described herein.
Embodiment three
A kind of preparation method of Milrinone injection, wherein the dosage (1000 parenteral solutions) of the Milrinone injection
For：
Milrinone 3g
Sodium chloride 45g
Water for injection is to 5L
The preparation method of Milrinone injection includes the following steps：
A, 4L waters for injection are measured and are heated to 60-65 DEG C, nitrogen is passed through after heating, and keep always leading in process for preparation
Enter nitrogen, be slowly added to lactic acid and the pH value of solution is adjusted to 1.6-2.0；
B, to the solution high-speed stirred prepared in step a, speed of agitator is not less than 200rpm, while 3g is added in into solution
Milrinone, until it is completely dissolved；
C, the solution prepared into step b adds in 45g sodium chloride, stirs to it and is completely dissolved；
D, the solution prepared into step c adds in a concentration of 10% sodium hydroxide solution, to adjust the pH value of solution extremely
2.9-3.4；
E, adding the water for injection of remaining dosage makes the solution of preparation be 5L, carries out refined filtration after being sufficiently stirred successively and surpasses
Filter.
In the present embodiment, the heating temperature of water for injection is preferably 62 DEG C in step a, and lactic acid adjusts the pH to 1.8 of solution,
PH value is adjusted to 2.9 by sodium hydroxide solution in step d.
There is step f after step e, then the filling sealing of solution prepared by step e sterilizes under hot pressing environment,
And it is 115 DEG C, pressure 97kPa to set the temperature of hot pressing environment, sterilization time is 15 minutes, to be carried out at sterilizing to parenteral solution
Reason.
Advantageous effect in the present embodiment is with consistent in embodiment one, and details are not described herein.
In order to preferably embody the storage stability and clarity that embodiment in the present invention compares existing preparation method, application
People has carried out a large number of experiments, and content of the test is following (dosage is 1000 components)：
Comparative example 1
Milrinone 5g
Sodium chloride 42.5g
Water for injection is to 5L
Preparation method includes the following steps：
A, 4L waters for injection are measured, and water for injection is heated, make water for injection temperature control system at 30-40 DEG C,
Nitrogen is passed through, process for preparation is kept to lead to nitrogen always, is added in the state of high-speed stirred into solution
Formula ratio milrinone, adding in lactic acid is completely dissolved milrinone；
B, formula ratio sodium chloride is added in, stirring makes to be completely dissolved；Continue that pH is adjusted to 2.8-3.5 with lactic acid；
Benefit adds to the full amount of water for injection, refined filtration；
C, step b solution is subjected to ultrafiltration, filters out the substances such as pyrogen in solution；
D, after filling sealing, 115 DEG C of pressure sterilizings 15 minutes, finished product.
Comparative example 2：
Milrinone 5g
Sodium chloride 42.5g
Water for injection is to 5L
Preparation method includes the following steps：
A, 4L waters for injection are measured, and water for injection is heated, water for injection temperature control system is made to be passed through nitrogen at 20-30 DEG C,
Process for preparation is kept to lead to nitrogen always, lactic acid is slowly added to and pH is adjusted to 2.8-3.5 ranges, in the state of high-speed stirred, to
Formula ratio milrinone is added in solution, is made it completely dissolved；
B, adding in the stirring of formula ratio sodium chloride makes to be completely dissolved；PH is adjusted to 2.8-3.5 ranges with lactic acid；Add injection
Water is to full dose, refined filtration；
C, step b solution is subjected to ultrafiltration, filters out the substances such as pyrogen in solution.
D, after filling sealing, 115 DEG C of pressure sterilizings 15 minutes, finished product.
Comparative example 3-6
Milrinone 5g
Sodium chloride 42.5g
Water for injection is to 5L
Preparation method includes the following steps：
A, 4L waters for injection are measured, and water for injection is heated, water for injection temperature control system is made to be passed through nitrogen at 20-30 DEG C,
Process for preparation is kept to lead to nitrogen always, lactic acid is slowly added to and pH is adjusted to 2.8-3.5 ranges, in the state of high-speed stirred, to
Formula ratio milrinone is added in solution, is made it completely dissolved；
B, formula ratio sodium chloride is added in, stirring makes to be completely dissolved；PH is adjusted to 2.8-3.5 ranges with lactic acid；Add injection
With water to full dose, refined filtration；
C, the activated carbon added in into step b solution filters after stirring 20min.
D, after refined filtration, after filling sealing, 115 DEG C of pressure sterilizings 15 minutes, finished product.
The formula of comparative example 3-6 is identical with preparation process, differs only in the concentration of activated carbon added in step c not
Together, the concentration of activated carbon of different comparative examples is as follows：
| Serial number | Concentration of activated carbon (g/ml) |
| Comparative example 3 | 0.05% |
| Comparative example 4 | 0.1% |
| Comparative example 5 | 0.15% |
| Comparative example 6 | 0.2% |
According to embodiment 1-3, method described in contrast test 1-3 prepares three batches of samples respectively, takes each batch sample 500
Branch, prior to -10~-20 DEG C place 48 hours, then 40 DEG C place 48 hours, so in triplicate after, checked whether there is by branch
Turbid phenomenon occurs, and counts.
Comparing result 1 is as shown in following table：
By above-mentioned comparing result 1, each batch of sample does not occur sample turbid phenomenon in embodiment 1-3, and contrast test
Each batch of sample has a certain number of samples to occur muddy in 1-3, illustrates the preparation side of Milrinone injection of the present invention
Method has preferable stability.
Result of the test 2
In the sample preparation procedure of embodiment 1-3 and reference examples 1-6, before and after depyrogenation is gone to operate, measure respectively
The concentration and its drug loss of drug, as a result as follows in liquid：
| Serial number | Lot number | Go depyrogenation prodrug concentration | Remove drug concentration after depyrogenation | Drug loss |
| Embodiment 1 | 150511 | 99.9% | 99.9% | 0.0% |
| Embodiment 2 | 150521 | 100.2% | 100.1% | 0.1% |
| Embodiment 3 | 150531 | 99.9% | 99.9% | 0.0% |
| Reference examples 1 | 150541 | 100.5% | 94.6% | 5.9% |
| Reference examples 2 | 150551 | 99.8% | 85.3% | 14.5% |
| Reference examples 3 | 150561 | 100.2% | 76.2% | 24.0% |
| Reference examples 4 | 150571 | 100.3% | 68.1% | 32.2% |
| Reference examples 5 | 150581 | 100.1% | 86.2% | 13.9% |
| Reference examples 6 | 150591 | 100.3% | 78.2% | 22.1% |
Conclusion：Before and after pyrogen removal, embodiment 1-3 drug concentrations are almost unchanged, and contrast test 3-6,
The concentration of drug changes greatly, and drug loss is apparent, illustrates to remove depyrogenation ratio by ultrafiltration in the present invention
Tradition is good using the effect of activated carbon.
Result of the test 3
The sample as prepared by embodiment 1, embodiment 2, contrast test 1,2 method of contrast test, takes certain amount to be positioned over
Under 40 DEG C of acceleration environments, sample appearance, medicament contg and the situation of change in relation to substance are observed 0,3, June.
Wherein, detection method of content：It is filler with octadecylsilane chemically bonded silica；With water-methanol-sodium borate buffer
Liquid (725:250:25) it is mobile phase；Detection wavelength is 254nm.Precision measures Milrinone injection 5ml, puts in 50ml measuring bottles,
Scale is diluted to mobile phase, is shaken up, as test solution, precision measures 20ul, injects liquid chromatograph, records chromatography
Figure；Separately take milrinone reference substance, it is accurately weighed, add flowing phased soln and quantify dilution be made it is molten containing about 0.1mg in every 1ml
Liquid is measured in the same method.
Substance-measuring method：With water-methanol-sodium borate buffer liquid (725:250:25) it is mobile phase；Detection wavelength is
254nm.Precision measures appropriate Milrinone injection, quantitatively diluted with mobile phase be made it is molten containing about milrinone 2ug in every 1ml
Liquid, as contrast solution；Precision measures Milrinone injection, each 20ul of contrast solution, is injected separately into liquid chromatograph, records color
Spectrogram is to 3 times of principal component peak retention time.
Result of the test such as following table：
Conclusion：Embodiment 1-3 appearances and content are almost unchanged, and the content of reference examples 1-3 declines apparent, cosmetic variation
Also clearly, illustrate the steady of the Milrinone injection that the preparation method by Milrinone injection of the present invention is prepared into
Qualitative and clarity is preferable.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
With within principle, any modification, equivalent replacement, improvement and so on should all be included in the protection scope of the present invention god.
Claims (10)
1. a kind of preparation method of Milrinone injection, the dispensing of the Milrinone injection are：Milrinone, lactic acid, sodium chloride
And water for injection, it is characterised in that the preparation method of the Milrinone injection includes the following steps：
A, 7/10-9/10 and the heating of the water for injection dosage are measured, nitrogen is passed through after heating, and keep in process for preparation
Always nitrogen is passed through, the lactic acid is slowly added to and the pH value of solution is adjusted；
B, to the solution high-speed stirred prepared in step a, while the milrinone is added in, until it is completely dissolved；
C, the solution prepared into step b adds in the sodium chloride, stirs to it and is completely dissolved；
D, the solution prepared into step c adds in sodium hydroxide solution, to adjust the pH value of solution；
E, the water for injection of remaining dosage is added, carries out refined filtration and ultrafiltration after being sufficiently stirred successively.
2. the preparation method of Milrinone injection according to claim 1, it is characterised in that：
The dosage of the Milrinone injection is as follows：
Milrinone 3-6g
Sodium chloride 40-45g
Appropriate water for injection, the solution for making preparation are 5L.
3. the preparation method of Milrinone injection according to claim 1, it is characterised in that：Water for injection in step a
Heating temperature is 60-65 DEG C.
4. the preparation method of Milrinone injection according to claim 1, it is characterised in that：By the pH of solution in step a
Value is adjusted to 1.6-2.0.
5. the preparation method of Milrinone injection according to claim 1, it is characterised in that：The sodium hydroxide solution
A concentration of 10%.
6. the preparation method of Milrinone injection according to claim 1, it is characterised in that：By the pH of solution in step d
Value is adjusted to 2.9-3.4.
7. the preparation method of Milrinone injection according to claim 1, it is characterised in that：0.22 is used during refined filtration
μm miillpore filter.
8. the preparation method of the Milrinone injection according to any one of claim 1-7, it is characterised in that：In step e,
Ultrafiltration will be carried out after solution refined filtration.
9. the preparation method of Milrinone injection according to claim 8, it is characterised in that：There is step after step e
F, the filling sealing of solution prepared step e, then sterilizes under hot pressing environment.
10. the preparation method of Milrinone injection according to claim 9, it is characterised in that：The temperature of the hot pressing environment
It is 115 DEG C, pressure 97kPa to spend, and sterilization time is 15 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810164860.7A CN108158988B (en) | 2018-02-27 | 2018-02-27 | Preparation method of milrinone injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810164860.7A CN108158988B (en) | 2018-02-27 | 2018-02-27 | Preparation method of milrinone injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108158988A true CN108158988A (en) | 2018-06-15 |
| CN108158988B CN108158988B (en) | 2021-03-23 |
Family
ID=62510638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810164860.7A Active CN108158988B (en) | 2018-02-27 | 2018-02-27 | Preparation method of milrinone injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108158988B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156753A (en) * | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| CN1679566A (en) * | 2004-04-07 | 2005-10-12 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
| CN101152180A (en) * | 2007-09-06 | 2008-04-02 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing milrinone |
| CN102525890A (en) * | 2010-12-17 | 2012-07-04 | 北大方正集团有限公司 | Milrinone injection and preparation method thereof |
| CN102552121A (en) * | 2010-12-22 | 2012-07-11 | 北大方正集团有限公司 | Milrinone injection |
| CN103655562A (en) * | 2012-09-25 | 2014-03-26 | 天津市嵩锐医药科技有限公司 | Stable milrinone medicament composition for injection |
-
2018
- 2018-02-27 CN CN201810164860.7A patent/CN108158988B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156753A (en) * | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| CN1679566A (en) * | 2004-04-07 | 2005-10-12 | 鲁南制药集团股份有限公司 | Milrinone sodium chloride injection and production thereof |
| CN101152180A (en) * | 2007-09-06 | 2008-04-02 | 鲁南制药集团股份有限公司 | Pharmaceutical composition containing milrinone |
| CN102525890A (en) * | 2010-12-17 | 2012-07-04 | 北大方正集团有限公司 | Milrinone injection and preparation method thereof |
| CN102552121A (en) * | 2010-12-22 | 2012-07-11 | 北大方正集团有限公司 | Milrinone injection |
| CN103655562A (en) * | 2012-09-25 | 2014-03-26 | 天津市嵩锐医药科技有限公司 | Stable milrinone medicament composition for injection |
Non-Patent Citations (1)
| Title |
|---|
| 王振宇等: "《生物活性成分分离技术》", 31 May 2015, 哈尔滨工业大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108158988B (en) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102924302A (en) | Injection-grade ambroxol hydrochloride and solution for inhalation of injection-grade ambroxol hydrochloride | |
| CN108992400B (en) | Pharmaceutical composition containing irinotecan hydrochloride and preparation method thereof | |
| CN106692124A (en) | Acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN110227063A (en) | A kind of preparation method of Linezolid Injection | |
| CN108158988A (en) | The preparation method of Milrinone injection | |
| CN101190214B (en) | Paclitaxel injection and preparation method thereof | |
| CN105640876B (en) | A kind of preparation process of moxifloxacin hydrochloride injection | |
| CN116763727A (en) | Etoposide injection and preparation method thereof | |
| JP2016528261A (en) | Chlorogenic acid powder injection and method for producing the same | |
| CN105213301B (en) | Netilmicin sulfate injection and its quality control method | |
| CN108685846B (en) | Levofloxacin hydrochloride injection and preparation method thereof | |
| CN103463122B (en) | Compound fluorouracil injection as well as preparation method thereof | |
| CN102988281A (en) | Injection of ambroxol hydrochloride and preparation method thereof | |
| CN107157926B (en) | Preparation method of docetaxel injection | |
| CN116350579A (en) | Clear propofol injection and preparation method thereof | |
| AU2016315877A1 (en) | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same | |
| CN110314132B (en) | Ornithine aspartate injection and preparation method thereof | |
| CN106420599B (en) | Preparation method of citric acid caffeine injection | |
| CN111529485B (en) | Preparation method of levetiracetam concentrated solution for injection | |
| CN104721223B (en) | A kind of injection pharmaceutical composition of compound electrolyte and preparation method thereof | |
| CN104922061B (en) | Nalmefene hydrochloride injection pharmaceutical composition and preparation method | |
| CN115282116B (en) | Amikacin injection and preparation method thereof | |
| CN116370601A (en) | Preparation method of ornithine aspartate injection | |
| CN113116921B (en) | Sodium bicarbonate injection and preparation method thereof | |
| CN114533683B (en) | Adenosylcobalamin freeze-dried preparation composition for injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Le Inventor after: Yang Xin Inventor before: Wang Le |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |